These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

340 related articles for article (PubMed ID: 2442078)

  • 41. In vitro studies on the fibrinolytic, thrombolytic and fibrinogenolytic properties of a tissue plasminogen activator from guinea pig keratocytes.
    Electricwala A; Ling RJ; Sutton PM; Griffiths B; Riley PA; Atkinson T
    Thromb Haemost; 1985 Apr; 53(2):200-3. PubMed ID: 4040659
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Effect of standard heparin and a low molecular weight heparin on thrombolytic and fibrinolytic activity of single-chain urokinase plasminogen activator in vitro.
    Lourenço DM; Dosne AM; Kher A; Samama M
    Thromb Haemost; 1989 Nov; 62(3):923-6. PubMed ID: 2556812
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Relationship of fibrinolysis and platelet function to bleeding after cardiopulmonary bypass.
    Ray MJ; Marsh NA; Hawson GA
    Blood Coagul Fibrinolysis; 1994 Oct; 5(5):679-85. PubMed ID: 7865673
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Activation of fibrin-bound plasminogen by pro-urokinase and its complementariness with that by tissue plasminogen activator.
    Gurewich V
    Enzyme; 1988; 40(2-3):97-108. PubMed ID: 2971533
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Biological and thrombolytic properties of proenzyme and active forms of human urokinase--I. Fibrinolytic and fibrinogenolytic properties in human plasma in vitro of urokinases obtained from human urine or by recombinant DNA technology.
    Zamarron C; Lijnen HR; Van Hoef B; Collen D
    Thromb Haemost; 1984 Aug; 52(1):19-23. PubMed ID: 6495259
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Pharmacokinetics of saruplase, a recombinant unglycosylated human single-chain urokinase-type plasminogen activator and its effects on fibrinolytic and haemostatic parameters in healthy male subjects.
    de Boer A; Kluft C; Gerloff J; Dooijewaard G; Günzler WA; Beier H; van der Meer FJ; Cohen AF
    Thromb Haemost; 1993 Aug; 70(2):320-5. PubMed ID: 8236142
    [TBL] [Abstract][Full Text] [Related]  

  • 47. [Molecular mechanisms of thrombolytic therapy].
    Lijnen HR; Collen D
    Haemostasis; 1986; 16 Suppl 4():3-15. PubMed ID: 2945768
    [No Abstract]   [Full Text] [Related]  

  • 48. Pharmacokinetics and pharmacodynamics of saruplase, an unglycosylated single-chain urokinase-type plasminogen activator, in patients with acute myocardial infarction.
    Koster RW; Cohen AF; Hopkins GR; Beier H; Günzler WA; van der Wouw PA
    Thromb Haemost; 1994 Nov; 72(5):740-4. PubMed ID: 7534946
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Enhanced thrombolysis in plasma and in vivo by single-chain urokinase-type plasminogen activator (scuPA) conjugated to an antifibrin antibody.
    Bode C; Runge M; Eberle T; Freitag M; Kübler W; Haber E
    Trans Assoc Am Physicians; 1989; 102():7-12. PubMed ID: 2517856
    [No Abstract]   [Full Text] [Related]  

  • 50. [A hybrid molecule of pro-urokinase and a fibrin-specific, monoclonal antibody fragment is a more effective thrombolytic agent than pro-urokinase in vitro and in vivo].
    Bode C; Eberle T; Runge M; Haber E; Kübler W
    Verh Dtsch Ges Inn Med; 1990; 96():1-3. PubMed ID: 2128723
    [No Abstract]   [Full Text] [Related]  

  • 51. Fluorogenic fibrinogen and fibrin facilitate macromolecular assembly and dynamic assay of picomolar levels of plasminogen activators under well mixed conditions.
    Wu JH; Diamond SL
    Thromb Haemost; 1995 Aug; 74(2):711-7. PubMed ID: 8585011
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Recombinant human C1-inhibitor prevents non-specific proteolysis by mutant pro-urokinase during optimal fibrinolysis.
    Gurewich V; Pannell R
    Thromb Haemost; 2009 Aug; 102(2):279-86. PubMed ID: 19652878
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Effects of kringles derived from human plasminogen on fibrinolysis in vitro.
    Sugiyama N; Iwamoto M; Abiko Y
    Thromb Res; 1987 Aug; 47(4):459-68. PubMed ID: 2821651
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Fibrinogenolysis and fibrinolysis in normal volunteers and patients with thrombosis after infusion of urokinase.
    Urano T; Kamiya T; Sakaguchi S; Takada Y; Takada A
    Thromb Res; 1985 Jul; 39(2):145-55. PubMed ID: 3161212
    [TBL] [Abstract][Full Text] [Related]  

  • 55. [Changes in the components of the animal fibrinolytic system induced by the action of physiological activators and enzymes of fungal origin].
    Andreenko GV; Serebriakova TN; Shimonaeva EE; Liutova LV; Karabasova MA
    Nauchnye Doki Vyss Shkoly Biol Nauki; 1983; (3):51-4. PubMed ID: 6342687
    [TBL] [Abstract][Full Text] [Related]  

  • 56. A comparative study of the promotion of tissue plasminogen activator and pro-urokinase-induced plasminogen activation by fragments D and E-2 of fibrin.
    Liu JN; Gurewich V
    J Clin Invest; 1991 Dec; 88(6):2012-7. PubMed ID: 1836471
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Synergism of tissue-type plasminogen activator (t-PA) and single-chain urokinase-type plasminogen activator (scu-PA) on clot lysis in vitro and a mechanism for this effect.
    Gurewich V; Pannell R
    Thromb Haemost; 1987 Jun; 57(3):372-3. PubMed ID: 3116707
    [No Abstract]   [Full Text] [Related]  

  • 58. Role of dextran sulfate in urokinase therapy and evaluation of the effects by estimation of plasmin inhibitor, fibrinogenolytic degradation products, and fibrinolytic degradation products.
    Hasegawa H; Nagata H; Yamauchi M; Murakoshi T; Oguma Y; Takei H; Seya T; Murao M
    Jpn Heart J; 1982 May; 23(3):339-47. PubMed ID: 6178853
    [TBL] [Abstract][Full Text] [Related]  

  • 59. [Thrombolysis using tissue-type plasminogen activator and pro-urokinase: synergism; mutants and hybrids].
    Páramo JA; Fernández FJ; Cuesta B; Paloma MJ; Rocha E
    Sangre (Barc); 1989 Aug; 34(4):297-9. PubMed ID: 2505395
    [No Abstract]   [Full Text] [Related]  

  • 60. Coronary thrombolysis in dogs with intravenously administered human pro-urokinase.
    Collen D; Stump D; van de Werf F; Jang IK; Nobuhara M; Lijnen HR
    Circulation; 1985 Aug; 72(2):384-8. PubMed ID: 3924437
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 17.